Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

Overview

The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for major depressive disorder (MDD).

Full Title of Study: “A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: January 2010

Detailed Description

It is retrospective patient chart study among psychiatrists and primary care physicians (PCPs) treating patients suffering from major depressive disorder (MDD). Physicians will be asked general medical questions in order to quantify their prescribing behavior and their perception of treatment performance. A retrospective patient chart review will then be performed and patient data will be collected to document patient characteristics and actual treatment outcomes. Upon qualification, specific instructions for chart review will be provided. Once the identified charts are pulled, the physicians are instructed to continue with the on-line survey. In total, there will be approximately 450 psychiatrists and 450 primary care physicians participating in this trial.

Interventions

  • Other: Pristiq first-line treatment charts
    • 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
  • Other: Pristiq second-line treatment charts
    • 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
  • Other: SNRI or SSRI first-line treatment charts
    • 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
  • Other: SNRI or SSRI second-line treatment charts
    • 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).

Arms, Groups and Cohorts

  • Patients initiated on Pristiq as a first line treatment
  • Patients initiated on Pristiq as a 2nd-line treatment
  • Patients initiated on a SNRI or SSRI as a first-line treatment
  • Patients initiated on a SNRI or SSRI as a 2nd-line treatment

Clinical Trial Outcome Measures

Primary Measures

  • 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.
    • Time Frame: 6 months
  • 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI).
    • Time Frame: 6 months
  • 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment.
    • Time Frame: 6 months
  • 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
    • Time Frame: 6 months

Secondary Measures

  • Incidence of adverse events and Incidence of discontinuation due to adverse events
    • Time Frame: 6 months
  • Percent of patients experiencing relapse
    • Time Frame: 6 months
  • Length of time to relapse
    • Time Frame: 6 months
  • Percent of discontinuation / medication switches due to lack of efficacy
    • Time Frame: 6 months
  • Subjective physician assessment of symptom control
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy. – Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company. Exclusion Criteria:

  • Patients who have not been treated for depression.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer
  • Provider of Information About this Clinical Study
    • Director, Clinical Trial Disclosure Group, Pfizer, Inc.
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.